title: Autologous transplantation for diffuse aggressive non-Hodgkin's lymphoma in patients never achieving remission: a report from the Autologous Blood and Marrow Transplant Registry.
abstract: OBJECTIVE
  To evaluate the results of high-dose chemotherapy and autologous hematopoietic stem-cell transplantation (autotransplants) in patients with diffuse aggressive non-Hodgkin's lymphoma (NHL) who never achieve a complete remission with conventional chemotherapy.
  
  
  METHODS
  Detailed records from the Autologous Blood and Marrow Transplant Registry (ABMTR) on 184 patients with diffuse aggressive NHL who never achieved a complete remission with conventional chemotherapy and subsequently received an autotransplant were evaluated. Transplants were performed between 1989 and 1995 and were reported to the ABMTR by 48 centers in North and South America.
  
  
  RESULTS
  Seventy-nine (44%) of 184 patients achieved a complete remission or a complete remission with residual imaging abnormalities of unknown significance after autotransplantation. Thirty-four (19%) of 184 had a partial remission and 55 (31%) of 184 had no response or progressive disease. Eleven patients (6%) were not assessable for response because of early death. The probabilities of progression-free and overall survival at 5 years after transplantation were 31% (95% confidence interval [CI], 24% to 38%) and 37% (95% CI, 30% to 45%), respectively. In multivariate analysis, chemotherapy resistance, Karnofsky performance status score less than 80 at transplantation, age > or = 55 years at transplantation, receiving three or more prior chemotherapy regimens, and not receiving pre- or posttransplant involved-field irradiation therapy were adverse prognostic factors for overall survival.
  
  
  CONCLUSIONS
  High-dose chemotherapy and autologous hematopoietic stem-cell transplantation should be considered for patients with diffuse aggressive NHL who never achieve a complete remission but who are still chemotherapy-sensitive and are otherwise transplant candidates.
authors.affiliation: Lymphoma Working Committee of the Autologous Blood and Marrow Transplant Registry, Health Policy Institute, Medical College of Wisconsin, Milwaukee, WI, USA. jvose@unmc.edu
authors.forename: J M
authors.initials: JM
authors.lastname: Vose
authors.forename: M J
authors.initials: MJ
authors.lastname: Zhang
authors.forename: P A
authors.initials: PA
authors.lastname: Rowlings
authors.forename: H M
authors.initials: HM
authors.lastname: Lazarus
authors.forename: B J
authors.initials: BJ
authors.lastname: Bolwell
authors.forename: C O
authors.initials: CO
authors.lastname: Freytes
authors.forename: S
authors.initials: S
authors.lastname: Pavlovsky
authors.forename: A
authors.initials: A
authors.lastname: Keating
authors.forename: B
authors.initials: B
authors.lastname: Yanes
authors.forename: K
authors.initials: K
authors.lastname: van Besien
authors.forename: J O
authors.initials: JO
authors.lastname: Armitage
authors.forename: M M
authors.initials: MM
authors.lastname: Horowitz
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002648:Child; D003131:Combined Modality Therapy; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D018365:Neoplasm, Residual; D016016:Proportional Hazards Models; D012074:Remission Induction; D016019:Survival Analysis; D014182:Transplantation, Autologous